Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck × camrelizumab × 1 year × Clear all

NCT07432087 2026-02-25

Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07400094 2026-02-10

NeoCamre-HN

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Mouth Neoplasms

NCT05156970 2025-07-31

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck